Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
teC9Gcw4JEXfQRaP